Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I Multiple-Ascending Dose (Japan) (MAD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00538174
First received: October 1, 2007
Last updated: March 20, 2015
Last verified: March 2015
  Purpose
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic Japanese subjects administered for 14 days

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: Dapagliflozin
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • AEs, vital signs & physical exam [ Time Frame: scr, Days -3, -1, 1, 2, 7, 12, 13, 14, 15, 21 ]
  • ECGs [ Time Frame: scr, Days -1, 1, 2, 7, 12, 13, 14, 15, 21 ]
  • Clinical labs [ Time Frame: scr, Days -1, 2, 7, 12, 14, 15, 21 ]
  • Urine safety markers [ Time Frame: Days -1, 1, 14 ]

Secondary Outcome Measures:
  • 24 hr PK blood & urine samples [ Time Frame: Days 1 & 14 ]
  • Serum glucose, serum insulin, serum c-peptide [ Time Frame: Days -1, 1, 14 ]
  • Serum fructosamine [ Time Frame: Days -1, 14, 4 h ]
  • OGTT [ Time Frame: Days -2, 13 (after 10 h fast) ]
  • 24h urine [ Time Frame: Days -1, 1 & 14 for glucose, creatinine & calcium ]

Enrollment: 36
Study Start Date: November 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
2.5 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Experimental: Arm 2
10 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Experimental: Arm 3
20 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Placebo Comparator: Arm 4 Drug: placebo
Tablets, Oral, 0 mg, once daily, up to 14 days

  Eligibility

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Japanese male and female subjects
  • Ages 20 to 70 years old
  • Established diagnosis of T2DM
  • BMI < 32 kg/m2
  • Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone
  • HbA1C 6.0 - 10.0%

Exclusion Criteria:

  • Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment
  • History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
  • History of incontinence or bladder dysfunction including nocturia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538174

Locations
Japan
Local Institution
Suita, Osaka, Japan, 5650853
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers K.K.
  More Information

Additional Information:
Publications:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00538174     History of Changes
Other Study ID Numbers: MB102-025
Study First Received: October 1, 2007
Last Updated: March 20, 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 25, 2017